Sunshine Biopharma Inc. (NASDAQ:SBFM) experienced a significant stock surge of 51.73%, reaching 55 cents per share, following the announcement of Canadian regulatory approval for its generic amoxicillin formulation. This approval marks a strategic expansion of the company's generic antibiotic portfolio, which aims to provide affordable treatments for various bacterial infections such as ear infections, pneumonia, and urinary tract infections. The generic amoxicillin product is set to be available in multiple dosage forms and strengths, with shipments to pharmacies anticipated by August 2026. The global market for amoxicillin is projected to grow, with sales revenue expected to range between $4.9 billion and $5.9 billion in 2025, potentially reaching approximately $6.4 billion by 2031. This growth is attributed to the increasing prevalence of bacterial infections and a rising demand for cost-effective antibiotic treatments. CEO Steve Slilaty expressed pride in adding amoxicillin to the company's offerings, highlighting its commitment to quality and compliance in delivering essential medications.